| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 50mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
Sodium cyanoboronhydride-d3 is a chemical reagent and does not target biological receptors or enzymes. Its mechanism of action is purely chemical: it serves as a source of hydride (or deuteride) ions for reduction reactions. In reductive amination reactions, the compound reduces iminium ions to amines by transferring a hydride (or deuteride) equivalent. The reducing power of sodium cyanoboronhydride-d3 is milder compared to sodium borohydride, allowing for selective reduction of imines and iminium ions in the presence of other reducible functional groups such as aldehydes and ketones. The compound is stable under acidic conditions (pH 3-4), which is advantageous for reductive amination reactions involving aldehydes or ketones and amines. The deuterated version is used to introduce deuterium atoms into target molecules, producing isotopically labeled compounds for use as internal standards or tracers in mass spectrometry-based quantification.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
Sodium cyanoboronhydride-d3 is not intended for biological activity evaluation in vitro. Its use is limited to chemical synthesis and analytical chemistry applications. In a typical in vitro chemical reduction experiment, the compound is used to reduce iminium ions or other reducible functional groups. For example, in reductive amination reactions, a mixture of an aldehyde or ketone (1 mmol) and an amine (1 mmol) is dissolved in methanol or acetonitrile, and sodium cyanoboronhydride-d3 (1-2 mmol) is added. The reaction mixture is stirred at room temperature for 2-24 hours. The progress of the reaction can be monitored by TLC or LC-MS. The product is a deuterium-labeled amine that can be used as an internal standard or tracer. The compound's reducing activity is concentration-dependent, and higher concentrations may lead to over-reduction or side reactions. The optimal concentration is typically 1-2 equivalents relative to the substrate. |
| ln Vivo |
Sodium cyanoboronhydride-d3 is a chemical reagent and does not exhibit in vivo biological activity. It is not intended for administration to animals as a therapeutic or diagnostic agent. However, the compound is frequently used in the synthesis of deuterium-labeled drugs or metabolites that are then used as internal standards in pharmacokinetic studies. After administration of a deuterium-labeled drug synthesized using sodium cyanoboronhydride-d3, the distribution, metabolism, and excretion of the labeled compound can be tracked by mass spectrometry. The reducing agent itself is not administered. Because sodium cyanoboronhydride-d3 is used only for chemical synthesis, no direct in vivo activity is relevant. The compound is handled in chemical laboratories under standard safety precautions for chemical reagents.
|
| Enzyme Assay |
A typical non-cellular protocol for using sodium cyanoboronhydride-d3 in reductive amination involves a standard synthetic chemistry workflow. In a round-bottom flask, 1 mmol of aldehyde or ketone and 1 mmol of primary or secondary amine are dissolved in 5 mL of anhydrous methanol or acetonitrile. The reaction mixture is stirred at room temperature for 30 minutes to allow imine formation. Then, 2 mmol of sodium cyanoboronhydride-d3 is added slowly with stirring. The reaction mixture is stirred at room temperature for 2-24 hours, and the progress is monitored by TLC (using silica gel plates and an appropriate solvent system) or by LC-MS. After completion, the solvent is evaporated under reduced pressure. The residue is taken up in ethyl acetate and washed with 1 N HCl (to remove excess amine), followed by saturated sodium bicarbonate and brine. The organic phase is dried over anhydrous sodium sulfate, filtered, and evaporated to yield the deuterated product. Purification by column chromatography may be performed if necessary. The product is identified by ¹H-NMR and mass spectrometry.
|
| Cell Assay |
A typical in vitro cell culture experiment using sodium cyanoboronhydride-d3 is not applicable, as the compound is a chemical reducing agent used in synthetic chemistry. It is not intended for direct addition to living cells due to its chemical reactivity and potential cytotoxicity. However, a protocol can be described for using the compound in cell lysates or for the synthesis of labeled compounds that are subsequently added to cells. For example, to study the uptake of a labeled compound, the compound is first synthesized using sodium cyanoboronhydride-d3 as described above. The purified labeled compound is then dissolved in an appropriate solvent (e.g., DMSO or PBS) and added to cells cultured in 96-well plates at a concentration of 1-100 uM. After incubation for 1-24 hours, cells are harvested, and the intracellular concentration of the labeled compound is quantified by LC-MS. The reducing agent itself is not added directly to live cells.
|
| Animal Protocol |
A typical in vivo animal study using sodium cyanoboronhydride-d3 is not directly performed, as the compound is a chemical reducing agent used in synthesis. However, a protocol can be described for using a deuterated compound synthesized with sodium cyanoboronhydride-d3 in animal studies. Male Sprague-Dawley rats (200-250 g) are administered the deuterated test compound via oral gavage or intravenous injection at a dose of 1-10 mg/kg. Blood samples (200 uL) are collected via the tail vein into EDTA-coated tubes at various time points (0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24 hours) post-dose. Plasma is separated by centrifugation (2,000 g, 10 minutes, 4degC). The plasma samples are processed by protein precipitation or liquid-liquid extraction, and the deuterated compound is quantified by LC-MS/MS using a calibration curve prepared with the same deuterated compound. The reducing agent itself is not administered to animals.
|
| ADME/Pharmacokinetics |
As a chemical reagent, sodium cyanoboronhydride-d3 is not characterized by typical pharmacokinetic parameters (Cmax, Tmax, AUC, half-life). It is not intended for in vivo administration as a test article. However, deuterated drugs or metabolites synthesized using this reagent can have altered pharmacokinetic properties compared to their non-deuterated counterparts. The kinetic isotope effect (KIE) may result in slower metabolism and potentially increased half-life for the deuterated analog. This property has been exploited in the development of deuterated drugs (e.g., deutetrabenazine) to improve metabolic stability. Formal PK studies of sodium cyanoboronhydride-d3 itself have not been conducted, as its sole purpose is to serve as a synthetic reagent for the preparation of deuterium-labeled compounds.
|
| Toxicity/Toxicokinetics |
Sodium cyanoboronhydride-d3 (sodium cyanoborodeuteride) is a toxic chemical reagent. The compound is harmful if swallowed, inhaled, or in contact with skin. It is also a flammable solid. The compound reacts with water to produce toxic gases, including hydrogen cyanide, which is highly toxic and potentially fatal. Standard laboratory safety precautions must be strictly followed: handle in a well-ventilated fume hood, wear appropriate personal protective equipment (gloves, lab coat, safety goggles), and avoid contact with water or moisture. In case of spillage, evacuate the area and follow the institutional hazardous material spill protocol. The compound should be stored in a tightly sealed container under an inert atmosphere (nitrogen or argon) at -20degC or in a cool, dry place, away from water and acids. It is for research use only and should not be used in humans or animals for therapeutic or diagnostic purposes.
|
| References | |
| Additional Infomation |
Sodium cyanoboronhydride-d3 (CAS# 25895-62-9) is a stable isotope-labeled reducing agent with a molecular weight of 65.86. Its molecular formula is CD3BNNa, and it is also known as sodium cyanoborodeuteride or NaBD3CN. The isotopic purity is typically greater than 98%, and the chemical purity is ≥95%. The compound is soluble in water (100 mg/mL) and polar organic solvents such as methanol, DMSO, and acetonitrile. It is a mild and selective reducing agent widely used in organic synthesis for the reductive amination of aldehydes and ketones and the reductive alkylation of amines. The deuterium labeling allows for the introduction of stable isotopes into target molecules, which is valuable for the synthesis of internal standards for mass spectrometry-based quantification. This product is for research use only and is not approved for clinical or veterinary applications.
|
| Molecular Formula |
CD3BNNA
|
|---|---|
| Molecular Weight |
65.86
|
| Exact Mass |
66.044
|
| CAS # |
25895-62-9
|
| PubChem CID |
23666334
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
>242ºC (dec.)(lit.)
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
4
|
| Complexity |
34.5
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H][B-]([2H])([2H])C#N.[Na+]
|
| InChi Key |
CVDUGUOQTVTBJH-MUTAZJQDSA-N
|
| InChi Code |
InChI=1S/CH3BN.Na/c2-1-3;/h2H3;/q-1;+1/i2D3;
|
| Chemical Name |
sodium;cyano(trideuterio)boranuide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 100 mg/mL (1518.37 mM）
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 15.1837 mL | 75.9186 mL | 151.8372 mL | |
| 5 mM | 3.0367 mL | 15.1837 mL | 30.3674 mL | |
| 10 mM | 1.5184 mL | 7.5919 mL | 15.1837 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
